Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Britain Courts Anthropic Amid US Defense Department Dispute 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 29 of the Danish Securities Trading Act, ALK has received notification from Jupiter Asset Management Ltd., that Jupiter Asset Management Ltd. in its capacity as investment manager for a number of clients now holds more than 5% of the share capital of ALK-Abelló A/S.
Jupiter Asset Management Ltd. now owns 5% of the company share capital equivalent to 506,562 B shares.
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
About ALK
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 2,200 employees, with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Torii, Abbott, and Seqirus to commercialise sublingual allergy immunotherapy tablets in Japan, Russia, South-East Asia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.
http://www.globenewswire.com/NewsRoom/AttachmentNg/ea4b2d62-c0a9-4e9e-bf69-65831455aa92
